SUNNYVALE, Calif., Jan. 28, 2013 /PRNewswire/ -- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, today announced the launch of the Company's new website at www.amarantus.com.
"2012 was an exceptionally productive year for Amarantus with the acquisition of two diagnostic platforms to expand our pipeline, the addition of several industry experts to our advisory boards, and positive efficacy data in our Traumatic Brain Injury program," said Gerald Commissiong, President and CEO. "We started 2013 demonstrating positive efficacy data for MANF in our Parkinson's program, and expect to make additional progress early this year with our diagnostic programs for chronic illnesses such as Parkinson's and Alzheimer's diseases."
To sign up for email alerts, click on the following link: http://www.amarantus.com/email-alerts.
About Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF)MANF (Mesencephalic-Astrocyte-derived Neurotrophic Factor) is a protein that corrects protein misfolding, one of the major causes of apoptosis (Programmed Cell Death). Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF) is believed to have broad potential because it is a naturally-occurring protein produced by the body for the purpose of reducing and preventing apoptosis (in response to injury or disease), via the unfolded protein response. By manufacturing MANF and administering it to the body, Amarantus is seeking to use a regenerative medicine approach to assist the body with higher quantities of MANF when needed. Amarantus is the front-runner and primary holder of intellectual property (IP) around MANF, and is initially focusing on the development of MANF-based protein therapeutics. MANF's current lead indication is Parkinson's disease with additional focus on Traumatic Brain Injury (TBI. Future indications may include myocardial infarction and certain rare and ultra-rare orphan diseases where MANF is currently being evaluated.